Floyd Petersen Sells 16,679 Shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) Stock

by · The Cerbat Gem

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH – Get Free Report) Director Floyd Petersen sold 16,679 shares of the stock in a transaction on Thursday, November 13th. The shares were sold at an average price of $26.49, for a total value of $441,826.71. Following the completion of the transaction, the director directly owned 75,531 shares in the company, valued at approximately $2,000,816.19. This represents a 18.09% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Amphastar Pharmaceuticals Price Performance

AMPH stock traded down $0.04 during mid-day trading on Monday, hitting $26.02. 417,693 shares of the stock were exchanged, compared to its average volume of 539,830. The company has a debt-to-equity ratio of 0.80, a current ratio of 3.29 and a quick ratio of 2.21. The stock has a market capitalization of $1.20 billion, a price-to-earnings ratio of 9.75 and a beta of 0.77. The business has a fifty day moving average price of $25.92 and a 200 day moving average price of $25.38. Amphastar Pharmaceuticals, Inc. has a 12 month low of $20.39 and a 12 month high of $46.43.

Amphastar Pharmaceuticals (NASDAQ:AMPH – Get Free Report) last announced its quarterly earnings data on Thursday, November 6th. The company reported $0.93 earnings per share for the quarter, beating analysts’ consensus estimates of $0.83 by $0.10. The company had revenue of $191.84 million for the quarter, compared to analysts’ expectations of $186.90 million. Amphastar Pharmaceuticals had a return on equity of 20.76% and a net margin of 18.64%. On average, sell-side analysts anticipate that Amphastar Pharmaceuticals, Inc. will post 3.49 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. Bank of America upped their price objective on shares of Amphastar Pharmaceuticals from $28.00 to $32.00 and gave the company a “neutral” rating in a research note on Tuesday, August 26th. Needham & Company LLC lowered their price target on Amphastar Pharmaceuticals from $36.00 to $34.00 and set a “buy” rating for the company in a research report on Friday, November 7th. Piper Sandler cut their target price on shares of Amphastar Pharmaceuticals from $30.00 to $25.00 and set a “neutral” rating on the stock in a research note on Friday, August 8th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Amphastar Pharmaceuticals in a report on Wednesday, October 8th. Finally, Zacks Research raised Amphastar Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Thursday, October 16th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, Amphastar Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $31.20.

Read Our Latest Stock Analysis on Amphastar Pharmaceuticals

Institutional Trading of Amphastar Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in the company. Signaturefd LLC raised its position in Amphastar Pharmaceuticals by 147.7% during the first quarter. Signaturefd LLC now owns 872 shares of the company’s stock valued at $25,000 after purchasing an additional 520 shares during the period. Farther Finance Advisors LLC boosted its holdings in shares of Amphastar Pharmaceuticals by 356.0% in the third quarter. Farther Finance Advisors LLC now owns 944 shares of the company’s stock valued at $25,000 after purchasing an additional 737 shares during the period. Global Retirement Partners LLC lifted its stake in Amphastar Pharmaceuticals by 219.0% in the third quarter. Global Retirement Partners LLC now owns 1,024 shares of the company’s stock worth $27,000 after acquiring an additional 703 shares during the period. MassMutual Private Wealth & Trust FSB increased its holdings in Amphastar Pharmaceuticals by 192.8% during the second quarter. MassMutual Private Wealth & Trust FSB now owns 1,262 shares of the company’s stock valued at $29,000 after buying an additional 831 shares during the period. Finally, Hantz Financial Services Inc. boosted its position in Amphastar Pharmaceuticals by 3,430.8% during the second quarter. Hantz Financial Services Inc. now owns 1,377 shares of the company’s stock valued at $32,000 after purchasing an additional 1,338 shares in the last quarter. Institutional investors own 65.09% of the company’s stock.

Amphastar Pharmaceuticals Company Profile

(Get Free Report)

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.

Featured Articles